Viral Hepatitis

You have full text access to this OnlineOpen article

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy†‡§

  1. Florian van Bömmel1,
  2. Bernhard Zöllner2,
  3. Christoph Sarrazin3,
  4. Ulrich Spengler4,
  5. Dietrich Hüppe5,
  6. Bernd Möller6,
  7. Heinz-Hubert Feucht2,
  8. Bertram Wiedenmann1,
  9. Thomas Berg1,¶,*

Article first published online: 26 JUL 2006

DOI: 10.1002/hep.21253

Issue

Hepatology

Hepatology

Volume 44, Issue 2, pages 318–325, August 2006

Additional Information

How to Cite

van Bömmel, F., Zöllner, B., Sarrazin, C., Spengler, U., Hüppe, D., Möller, B., Feucht, H.-H., Wiedenmann, B. and Berg, T. (2006), Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology, 44: 318–325. doi: 10.1002/hep.21253

Author Information

  1. 1

    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité—Campus Virchow-Klinikum; Universitätsmedizin Berlin, Berlin, Germany

  2. 2

    Institut für Medizinische Mikrobiologie und Immunologie, Universitäts-Krankenhaus Eppendorf, Hamburg, Germany

  3. 3

    Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany

  4. 4

    Zentrum für Innere Medizin, Universitätsklinikum Bonn, Bonn, Germany

  5. 5

    Gastroenterologische Gemeinschaftspraxis Herne, Herne, Germany

  6. 6

    Hepatologische Schwerpunktpraxis, Berlin, Germany

  1. fax: (49) 30-450-553903

*Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin; Germany

  1. †

    This study was presented in part at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, 2005.

  2. ‡

    Potential conflict of interest: Dr. van Bömmel and Dr. Zöllner received travel grants from Gilead. Dr. Berg consults for, advises, and is on the speakers' bureau for Gilead.

  3. §

    See Editorial on Page 309

  4. fax: (49) 30-450-553903

Publication History

  1. Issue published online: 26 JUL 2006
  2. Article first published online: 26 JUL 2006
  3. Manuscript Accepted: 27 APR 2006
  4. Manuscript Received: 20 DEC 2005

Funded by

  • German Competence Network for Viral Hepatitis (Hep-Net)
  • German Ministry of Education and Research (BMBF). Grant Number: 01 KI 0437
  • European Network of Excellence “Vigilance against Viral Resistance” (VIRGIL). Grant Number: EU-Project No. LSHM-CT-2004-503359

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (590K)

References

  • 1
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521–1531.
  • 2
    Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. HEPATOLOGY 2003; 37: 1309–1319.
    Direct Link:
  • 3
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808–816.
  • 4
    Perillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. HEPATOLOGY 2000; 32: 129–134.
    Direct Link:
  • 5
    Buti M, Cotrina M, Jardi R, De Castro EC, Rodriguez-Frias F, Sanchez-Avila F, et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 2001; 8: 270–275.
    Direct Link:
  • 6
    Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. HEPATOLOGY 2000; 32: 1172–1174.
  • 7
    Westland CE, Yang H, Delaney WE 4th, Wulfsohn M, Lama N, Gibbs CS, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12: 67–73.
    Direct Link:
  • 8
    Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91–101.
  • 9
    Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81–90.
  • 10
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292–297.
  • 11
    Yang H, Westland C, Delaney W IV, Angus PW, Locarnini SA, et al. Complete genotypic and phenotypic analyses of HBV mutations identifed in HBeAg-negative chronic hepatitis B patients receiving 96 weeks of adefovir dipivoxil (ADV) [Abstract]. HEPATOLOGY 2003; 38(Suppl): 705A.
  • 12
    Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [Abstract]. J Hepatol 2005; 42: 17.
  • 13
    Hadziyannis S, Tassopoulos N, Chang TT, Heathcote J, Kitis G, Rizzetto M, et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: Results after 5 years of therapy. HEPATOLOGY 2005; 42: LB14.
  • 14
    van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. HEPATOLOGY 2004; 40: 1421–1425.
    Direct Link:
  • 15
    Antoniou T, Raboud J, Chirhin S, Yoong D, Govan V, Gough K, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 2005; 6: 284–290.
    Direct Link:
  • 16
    van Bömmel F, Schernick A, Hopf U, Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 2003; 124: 586–587.
  • 17
    Núñez M, Pérez-Olmeda M, Díaz B, Ríos P, González-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16: 2352–2354.
  • 18
    Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186: 1844–1847.
  • 19
    Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348: 177–178.
  • 20
    van Bömmel F, Wünsche T, Schürmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. HEPATOLOGY 2002; 36: 507–508.
    Direct Link:
  • 21
    Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185–1192.
  • 22
    Schildgen O, Schewe CK, Vogel M, Daumer M, Kaiser R, Weitner L, et al. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 2004; 18: 2325–2327.
  • 23
    Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26: 1148–1153.
  • 24
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. HEPATOLOGY 1998; 27: 1670–1677.
    Direct Link:
  • 25
    Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus DNA in two international reference plasma preparations. HEPATOLOGY 2001; 33: 751–757.
    Direct Link:
  • 26
    Norder H, Hammas B, Löfdahl S, Couroucé AM, Magnius LO. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol 1992; 73: 1201–1208.
  • 27
    Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. HEPATOLOGY 2004; 39: 42–50.
    Direct Link:
  • 28
    Westland CE, Yang H, Delaney WE 4th, Wulfsohn M, Lama N, Gibbs CS, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12: 67–73.
    Direct Link:
  • 29
    Lampertico P, Marzano A, Levrero M, Santantonio T, Andreone P, Brunetto M, et al. A multicenter Italian study of rescue Adefovir Dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 604 patients [Abstract]. HEPATOLOGY 2005; 42(Suppl): 591A
  • 30
    Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283–90.
  • 31
    Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. HEPATOLOGY 2005; 42: 1414–1419.
    Direct Link:
  • 32
    Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9: 353–363.
  • 33
    Qi X, Delaney W IV, Ray AS, Yang H, Miller MD, Xiong S. In vitro characterisation of anti-HBV efficacy and intracellular metabolism of tenofovir [Abstract]. J Hepatol 2005; 42: 32.
  • 34
    Zídek Z, Kmoníčková E, Holý A. Involvement of adenosine A(1) receptors in upregulation of nitric oxide by acyclic nucleotide analogues. Eur J Pharmacol 2004; 501: 79–86.
  • 35
    Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890–1897.
  • 36
    Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750–1758.
View Full Article (HTML) Get PDF (590K)